Catalent And Minerva Neurosciences Enter Commercial Supply Agreement For Schizophrenia Drug…
Catalent and Minerva Neurosciences announced that they have entered into a long-term commercial supply agreement for roluperidone (MIN-101), an investigational compound under…
Read More...
Read More...
